Treace Medical Concepts, Inc. (TMCI)
After hours:
| Previous Close | 5.16 |
| Open | 5.25 |
| Bid | 5.04 x 700 |
| Ask | 5.07 x 500 |
| Day's Range | 4.94 - 5.29 |
| 52 Week Range | 3.92 - 27.41 |
| Volume | |
| Avg. Volume | 1,015,959 |
| Market Cap | 313.141M |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.60 |
GlobeNewswireTreace to Present at Truist Securities MedTech Conference
Tuesday, June 18, 2024 at 8:00 am Eastern TimePONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside
GuruFocus.comDirector Jane Kiernan Acquires 19,356 Shares of Treace Medical Concepts Inc (TMCI)
On May 14, 2024, Director Jane Kiernan purchased 19,356 shares of Treace Medical Concepts Inc (NASDAQ:TMCI), as reported in the SEC Filing.
GuruFocus.comDirector Deepti Jain Acquires 25,000 Shares of Treace Medical Concepts Inc (TMCI)
On May 10, 2024, Deepti Jain, Director at Treace Medical Concepts Inc (NASDAQ:TMCI), purchased 25,000 shares of the company, as reported in a recent SEC Filing.
